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.C. GUARDIAN Investigators 
A new multiprogr able implantable defibrillator with 
telemetry and bradycardia pacing capability (Telectronics 
GUARDIAR 4202) was implanted in 40 pts. The pt.population 
includes 32 males and 8 females with a mean age of 58.6 
years. The indication for implant was ventricular tachy- 
cardia (VT) in 19 pts. ventricular fibrillation in 9 pts. 
and VT/VP in 12 pts. Twenty pts. experienced sudden 
cerdiac death in association with their ventricular arrhy- 
thmia. The mean number of drugs failed equaled 2.8. The 
primary cardiovascular disease was coronary artery dis- 
ease with a mean ejection fractionnI35.7%. At the time 
of implant the mean number of inductions completed was 
5.6 and the mean implant defibrillation threshold was 13.9 
Joules. Apps*opriate programmed VP sensitivity was 1.0 mV 
in 26 pts. Appropriate bradycardia performance was docu- 
mented in 28 pts. at rbe time of implant. To date there 
have been 5 episodes of delivery of patients shocks for 
spontaneous ventricular arrhythmia events. There havebeen 
9 episodes of nonsustained arrhythmias that due todevices 
reconfirmation algorithm did not result in spurious shock 
delivery. There has been no incidence of inappropriate 
shock delivery due to failure to sense indicated ventri- 
cular arrhythmias. The complications that have been re- 
ported to date are those previously reported with implan- 
table defibrillators. CONCLUSION: Initial clinical 
experience with this new Implantable Defibrillator 
indicates that the device is performing according to 
design and specification. 
recurrent hemodynamica~~y stable, drug refractory sustained 
ventricular tachysardia (VT). Prior to implant of the AP, at 
least 50 inductions of VT were performed in each pt. All 
ere terminated successfully by the selected pacing sequence. 
the burst scanning mode of ventricular pacing was 
beats, scanning rates from 328~32 msec to 245223 
msec). Since the AlcD was intended to treat only accelerated 
episodes of VT, high rate cut off devices were used (192+12 
bpm). fter 14+4 months of follow-up, all 13 pts have used 
their TV ter~~ate a total of 3344 episodes of VT. 
presyncope or syncope and telemetry from the AP revealed 
sensed rates greater than the AICD cut off rates. No deaths 
occurred. 
mbination 
The large 
pacing, 
e preimp~a~t testing, an 
ccasionaily occur to treat accelerated 
episodes of VT in over 50% of the ptS. 
